MXPA04003689A - Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2. - Google Patents

Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2.

Info

Publication number
MXPA04003689A
MXPA04003689A MXPA04003689A MXPA04003689A MXPA04003689A MX PA04003689 A MXPA04003689 A MX PA04003689A MX PA04003689 A MXPA04003689 A MX PA04003689A MX PA04003689 A MXPA04003689 A MX PA04003689A MX PA04003689 A MXPA04003689 A MX PA04003689A
Authority
MX
Mexico
Prior art keywords
bone
methods
pharmaceutical compositions
administering
agonists
Prior art date
Application number
MXPA04003689A
Other languages
English (en)
Inventor
Wilker Korsmeyer Richard
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA04003689A publication Critical patent/MXPA04003689A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invencion se refiere a composiciones farmaceuticas y a procedimientos que comprenden agonistas de prostaglandinas, especificamente agonistas selectivos del receptor EP2, que son utiles para potenciar la reparacion y la curacion de los huesos y para restaurar o aumentar la masa osea en vertebrados, particularmente en mamiferos. Los agonistas selectivos del receptor EP2 de la presente invencion son eficaces en el tratamiento de afecciones tales como aquellas en las que el paciente tiene una fractura de union retrasada o sin union, un defecto oseo, fusion espinal, crecimiento oseo hacia el interior, reconstruccion craneofacial o puntos oseos con riesgo de fractura.
MXPA04003689A 2001-11-30 2002-10-21 Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2. MXPA04003689A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33515601P 2001-11-30 2001-11-30
PCT/IB2002/004368 WO2003045371A1 (en) 2001-11-30 2002-10-21 Pharmaceutical compositions and methods for administering ep2 receptor selective agonists

Publications (1)

Publication Number Publication Date
MXPA04003689A true MXPA04003689A (es) 2004-07-23

Family

ID=23310510

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003689A MXPA04003689A (es) 2001-11-30 2002-10-21 Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2.

Country Status (24)

Country Link
US (1) US20030166631A1 (es)
EP (1) EP1448182A1 (es)
JP (1) JP2005513030A (es)
KR (1) KR20040063981A (es)
CN (1) CN1599605A (es)
AR (1) AR037593A1 (es)
AU (1) AU2002348948A1 (es)
BR (1) BR0214614A (es)
CA (1) CA2468494A1 (es)
GT (1) GT200200235A (es)
HN (1) HN2002000336A (es)
IL (1) IL161834A0 (es)
MX (1) MXPA04003689A (es)
NO (1) NO20042272L (es)
NZ (1) NZ532209A (es)
PA (1) PA8559601A1 (es)
PE (1) PE20030660A1 (es)
PL (1) PL370914A1 (es)
RU (1) RU2004116318A (es)
SV (1) SV2004001417A (es)
TW (1) TW200300342A (es)
UY (1) UY27556A1 (es)
WO (1) WO2003045371A1 (es)
ZA (1) ZA200402795B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP2422814A1 (en) * 2003-07-25 2012-02-29 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
WO2005080367A1 (en) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
ES2564167T3 (es) 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
WO2007017687A2 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
JP2009529051A (ja) * 2006-03-07 2009-08-13 オステオスクリーン アイピー， エルエルシー ＨＭＧＣｏ−Ａレダクターゼ阻害剤による骨および軟骨の強化
NZ573964A (en) 2006-07-28 2010-11-26 Pfizer Prod Inc isopropyl [3-({[4-(1H-pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)-amino}methyl)phenoxy]acetate, a prostaglandin E2 receptor agonist (EP2), useful in lower intraocular pressure thereby treating glaucoma
EP2269611B1 (en) 2006-11-16 2016-03-23 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza A viral infection
WO2009025793A2 (en) * 2007-08-21 2009-02-26 Senomyx, Inc. Human t2r bitterness receptors and uses thereof
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
FR3034678A1 (fr) * 2015-04-07 2016-10-14 Geocorail Dispositif, procede et compose pour la reconstruction osseuse d'un vertebre.
RU2021103425A (ru) * 2016-02-12 2021-02-25 Блубёрд Био, Инк. Композиции, повышающие число копий вектора (чкв), и способы их применения
US11326183B2 (en) 2016-02-12 2022-05-10 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4789663A (en) * 1984-07-06 1988-12-06 Collagen Corporation Methods of bone repair using collagen
DE69738613T2 (de) * 1996-12-20 2009-04-30 Pfizer Inc. Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists

Also Published As

Publication number Publication date
TW200300342A (en) 2003-06-01
CN1599605A (zh) 2005-03-23
PE20030660A1 (es) 2003-08-04
EP1448182A1 (en) 2004-08-25
JP2005513030A (ja) 2005-05-12
AU2002348948A1 (en) 2003-06-10
PA8559601A1 (es) 2003-07-28
KR20040063981A (ko) 2004-07-15
SV2004001417A (es) 2004-02-24
UY27556A1 (es) 2003-06-30
NO20042272L (no) 2004-07-28
AR037593A1 (es) 2004-11-17
HN2002000336A (es) 2003-02-10
RU2004116318A (ru) 2005-03-27
NZ532209A (en) 2007-05-31
WO2003045371A1 (en) 2003-06-05
US20030166631A1 (en) 2003-09-04
BR0214614A (pt) 2004-09-14
ZA200402795B (en) 2005-04-13
IL161834A0 (en) 2005-11-20
PL370914A1 (en) 2005-06-13
GT200200235A (es) 2003-06-25
CA2468494A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
MXPA04003689A (es) Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2.
SG148037A1 (en) Fgf variants and methods for use thereof
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
DE602004011083D1 (de) Orthopädische implantat- und knochenschraubenanordnung
WO2005086953A3 (en) Device and method for fixing bone segments
MXPA04001334A (es) Materiales y metodos para promover la reparacion de tejido nervioso.
CA2334257A1 (en) Treatment of osteoporosis with ep2/ep4 receptor selective agonists
HK1053053A1 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies.
AU2003251729A8 (en) Use of antibodies against flt-1 for the treatment of osteoporosis
Tanaka et al. Use of an injectable complex of β-tricalcium phosphate granules, hyaluronate, and fibroblast growth factor-2 on repair of unstable intertrochanteric fractures
MXPA06000460A (es) Polipeptidos humanos, recombinantes, mejorados de interferon-beta-1b.
ZA202100897B (en) Composition for improved bone fracture healing
UA90745C2 (ru) Способ лечения чрез- и межвертельных переломов бедра у больных преклонного и старческого возраста
MD2299F1 (en) Method of patella fractures osteosynthesis
MD1270F1 (en) Method for treatment of the hand navicular bone pseudarthrosis
MD2630G2 (ro) Metodă de osteosinteză la fracturile periprotetice ale diafizei femurului
UA33416A (uk) Пристрій для остеосинтезу плоских кісток
DE60236411D1 (de) Verwendung von g-csf als zusätzliche behandlung in die wiederherstellung von bindegewebe
UA34163A (uk) Спосіб стимулювання остеогенезу при хірургічних втручаннях на кістках щелепи
UA36326A (uk) Пристрій для черезкісткового остеосинтезу поєднаних переломів таранної та п'яткової кісток
Nounla et al. The external transfixation of the knee joint in a case of an open comminuted femoral fracture
MD2000F1 (en) Method of reconstruction of viciously consolidated distal humerus metaphyseal fractures to children
UA101594U (ru) Способ лечения осколочных переломов, ложных суставов и переломов проксимального отдела бедра после металлоостеосинтеза
UA31717A (uk) Спосіб лікування внутрішньосуглобових переломів
UA41708A (uk) Спосіб лікування порушень регенерації кісткової тканини

Legal Events

Date Code Title Description
FA Abandonment or withdrawal